Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 5/20 | 0.65 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 2/20 | 0.44 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.44 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | TACR2 | P21452 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SHBG | P04278 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16050455 | 0.93 | GPR84 (1.00) | GPR84PTGS2CYP3A4ALDH1A1HSD17B10 | |
| SCHEMBL16050491 | 0.85 | GPR84 (0.84) | GPR84PTGS2CYP3A4ALDH1A1FUT7 | |
| SCHEMBL290207 | 0.85 | PTGS2 (0.67) | GPR84PTGS2CYP3A4ALDH1A1HSD17B10 | |
| SCHEMBL1690036 | 0.84 | PTGS2 (0.91) | GPR84PTGS2CYP3A4ALDH1A1ESR1 | |
| SCHEMBL4971459 | 0.82 | PTGS2 (0.91) | GPR84PTGS2CYP3A4ALDH1A1ESR1 | |
| SCHEMBL11782606 | 0.82 | PTGS2 (0.91) | GPR84PTGS2CYP3A4ALDH1A1ESR1 | |
| SCHEMBL11782699 | 0.82 | PTGS2 (0.91) | GPR84PTGS2CYP3A4ALDH1A1ESR1 | |
| SCHEMBL11331796 | 0.82 | PTGS2 (0.91) | GPR84PTGS2CYP3A4ALDH1A1ESR1 | |
| SCHEMBL6536156 | 0.82 | PTGS2 (0.91) | GPR84PTGS2CYP3A4ALDH1A1ESR1 | |
| SCHEMBL6535950 | 0.82 | PTGS2 (0.91) | GPR84PTGS2CYP3A4ALDH1A1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267779-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PROMETIC PHARMA SMT LIMITED (GB) | 2022-03-08 | — | — | US | disclosed |
| US-9439882-B2 | Compounds and compositions for the treatment of cancer | PROMETIC BIOSCIENCES INC. (CA) | 2016-09-13 | — | — | US | disclosed |
| US-20160023983-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, LIVER FIBROSIS,SKIN FIBROSIS AND CARDIAC FIBROSIS | PROMETIC BIOSCIENCES INC. (CA) | 2016-01-28 | — | — | US | disclosed |
| US-20150313856-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC PHARMA SMT LIMITED (GB) | 2015-11-05 | — | — | US | disclosed |
| US-20120088784-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2012-04-12 | — | — | US | disclosed |
| EP-2427416-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | ProMetic BioSciences Inc. (CA) | 2012-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160023983-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, LIVER FIBROSIS,SKIN FIBROSIS AND CARDIAC FIBROSIS | PAH, HRH3, CFH | PTGS2 1591/4885ADORA3 1276/4885PTGS1 1304/4885 |
| US-20150313856-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | DCK, TOP2B, TOP2A | PTGS2 2852/4885ADORA3 4423/4885PTGS1 2918/4885 |
| US-20120088784-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof | TYR, PAH, REN | PTGS2 613/4885ADORA3 340/4885PTGS1 409/4885 |
| US-11267779-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PAH, HRH3, CFH | PTGS2 1591/4885ADORA3 1276/4885PTGS1 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.